Case Report: Visceral leishmaniasis-associated hemophagocytic lymphohistiocytosis: three diagnostic pathways and a preventable diagnostic odyssey

Visceral leishmaniasis (VL) can trigger hemophagocytic lymphohistiocytosis (HLH), but the substantial overlap between severe leishmaniasis and the clinical criteria for HLH can obscure the underlying infection and delay pathogen-directed treatment, particularly in non-endemic settings. We describe three adults with VL-associated HLH who reached the same diagnosis through three distinct pathways. In the first patient, Leishmania amastigotes were identified on bone marrow smear during the evaluation of HLH. In the second, peripheral-blood metagenomic next-generation sequencing (mNGS) detected Leishmania early in the infectious work-up, allowing antiparasitic treatment to begin before etoposide was administered. In the third, recurrent fever and massive splenomegaly persisted despite approximately three months of etoposide-based treatment for presumed refractory HLH, while positron emission tomography/computed tomography (PET/CT) raised concern for lymphoma; the diagnosis was ultimately established by splenic biopsy and repeat bone marrow examination demonstrating Leishmania. Following antileishmanial therapy, all three patients showed resolution of fever and improvement of cytopenias, hyperferritinemia, and organomegaly, and no further HLH-directed cytotoxic chemotherapy was required after the infectious diagnosis was established. Together, these cases illustrate that VL may both mimic and drive the HLH phenotype, creating a potentially preventable diagnostic delay when the infectious cause is not considered early. Careful residence and travel history, together with timely pathogen-directed testing such as serology, bone marrow examination, and peripheral-blood mNGS when available, can facilitate earlier recognition. In suspected infection-associated HLH, identifying and treating the underlying pathogen is therefore central, while additional HLH-directed immunosuppressive therapy should be individualized according to the severity and persistence of hyperinflammation.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-16
DOI
https://doi.org/10.3389/fimmu.2026.2008773
Primary Topic
Research on Leishmaniasis Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Visceral leishmaniasis-associated hemophagocytic lymphohistiocytosis: three diagnostic pathways and a preventable diagnostic odyssey

Xushu Zhong, Yushuang Xiao, Ruilian Xie, Yang Dai et al.
2 links
Frontiers in Immunology
Research on Leishmaniasis Studies
article

Case Report: Visceral leishmaniasis-associated hemophagocytic lymphohistiocytosis: three diagnostic pathways and a preventable diagnostic odyssey

Xushu Zhong, Yushuang Xiao, Ruilian Xie, Yang Dai, Ailin Zhao, Yijun Wu, Ting Niu
article en

Abstract

Visceral leishmaniasis (VL) can trigger hemophagocytic lymphohistiocytosis (HLH), but the substantial overlap between severe leishmaniasis and the clinical criteria for HLH can obscure the underlying infection and delay pathogen-directed treatment, particularly in non-endemic settings. We describe three adults with VL-associated HLH who reached the same diagnosis through three distinct pathways. In the first patient, Leishmania amastigotes were identified on bone marrow smear during the evaluation of HLH. In the second, peripheral-blood metagenomic next-generation sequencing (mNGS) detected Leishmania early in the infectious work-up, allowing antiparasitic treatment to begin before etoposide was administered. In the third, recurrent fever and massive splenomegaly persisted despite approximately three months of etoposide-based treatment for presumed refractory HLH, while positron emission tomography/computed tomography (PET/CT) raised concern for lymphoma; the diagnosis was ultimately established by splenic biopsy and repeat bone marrow examination demonstrating Leishmania. Following antileishmanial therapy, all three patients showed resolution of fever and improvement of cytopenias, hyperferritinemia, and organomegaly, and no further HLH-directed cytotoxic chemotherapy was required after the infectious diagnosis was established. Together, these cases illustrate that VL may both mimic and drive the HLH phenotype, creating a potentially preventable diagnostic delay when the infectious cause is not considered early. Careful residence and travel history, together with timely pathogen-directed testing such as serology, bone marrow examination, and peripheral-blood mNGS when available, can facilitate earlier recognition. In suspected infection-associated HLH, identifying and treating the underlying pathogen is therefore central, while additional HLH-directed immunosuppressive therapy should be individualized according to the severity and persistence of hyperinflammation.

Frontiers in ImmunologyVol. 17
Sichuan University (CN), West China Medical Center of Sichuan University (CN), West China Hospital of Sichuan University (CN), State Key Laboratory of Biotherapy (CN)
Good health and well-being
Research on Leishmaniasis Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon